Home / Blurb / Discussion Detail

FDA Approves Lisocabtagene Maraleucel for R/R Large B-Cell Lymphoma

On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Read the FDA announcement.

Read the Bristol Myers Squibb announcement.

Posted 2/8/2021